These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1426900)

  • 1. [Suppressive effect of circulating immune complexes on cytotoxicity of blood lymphocytes in patients with chronic myeloid leukemia].
    Guseva SA; Fed'ko AA; Volobueva ZV
    Gematol Transfuziol; 1992 Feb; 37(2):10-2. PubMed ID: 1426900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
    Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.
    Choo QWW; Koean RAG; Chang SC; Chng WJ; Chan MC; Wang W; Er JZ; Ding JL
    Immunol Cell Biol; 2020 Feb; 98(2):138-151. PubMed ID: 31837284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
    Wagner WM; Ouyang Q; Pawelec G
    Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced NK activity during blast crisis in chronic myelogenous leukemia (CML).
    Delwail V; Meseri A; Brizard A; Lecron JC; Sadoun A; Costerousse F; Guilhot F; Tanzer J; Goube de Laforest P
    Leuk Res; 1992; 16(6-7):721-2. PubMed ID: 1635387
    [No Abstract]   [Full Text] [Related]  

  • 8. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDF-1α Reduces Human Natural Killer Cell Cytotoxicity against Chronic Myelogenous Leukemia K562 Cells.
    Mardomi A; Hossein-Nataj H; Jafari N; Mohammadi N; Abediankenari S
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(5):493-500. PubMed ID: 32245293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia as an immunological target.
    Lim SH; Coleman S
    Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic significance of natural cytotoxicity of lymphocytes in chronic leukemia].
    Guseva SA; Sivachenko TP; Fed'ko AA
    Vopr Onkol; 1991; 37(5):560-3. PubMed ID: 1767510
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake RJ; Advani S; Gangal SG
    Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of natural killer cells in the treatment of chronic myeloid leukemia.
    Silla LM; Whiteside TL; Ball ED
    J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
    Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
    J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
    Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
    Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
    Chang WC; Fujimiya Y; Casteel N; Pattengale P
    Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibody-dependent and natural cellular cytotoxic reactions in rheumatic diseases].
    Aleksandrova EN; Zimin IuI; Nasonov EL
    Ter Arkh; 1984; 56(10):130-6. PubMed ID: 6084315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.